Anti-HPV16E2 [HPV16E2]

Cervical intraepithelial neoplasia (CIN) is caused by human papillomavirus (HPV) infection and is the precursor to cervical carcinoma. The completion of the HPV productive life cycle depends on the expression of viral proteins. Initiation of the viral productive replication requires expression of the E2 viral protein that cooperates with the E1 viral DNA helicase. A […]

Contributors

Institute
A*STAR Accelerate Technologies Pte Ltd
Cat. #: 153202
Tool sub type: Primary antibody
Unit size: 100 ug
Cancer types: Cervical cancer
Research Fields: Cancer;Cell biology;Microbiology
Application: IHC ; WB
Target: HPV16E2
Reactivity: Human
Clone: HPV16E2
Host: Rabbit
Class: Polyclonal
Alternate name: Human papillomavirus type 16; Regulatory protein E2
Product description: Cervical intraepithelial neoplasia (CIN) is caused by human papillomavirus (HPV) infection and is the precursor to cervical carcinoma. The completion of the HPV productive life cycle depends on the expression of viral proteins. Initiation of the viral productive replication requires expression of the E2 viral protein that cooperates with the E1 viral DNA helicase. A novel and important role for the HPV16-E2 protein in controlling host cell cycle during malignant transformation was recently revealed. Xells expressing HPV16-E2 in vitro were arrested in prophase alongside activation of a sustained DDR signal. In vivo, HPV16-E2 protein is present in cells that express both mitotic and DDR signals specifically in CIN3 lesions, immediate precursors of cancer, suggesting that E2 may be one of the drivers of genomic instability and carcinogenesis in vivo.
Conjugation: Unconjugated
Immunogen: GST-HPV16 E2 (209365)
Immunogen Uniprot ID: TBC
Target background: Cervical intraepithelial neoplasia (CIN) is caused by human papillomavirus (HPV) infection and is the precursor to cervical carcinoma. The completion of the HPV productive life cycle depends on the expression of viral proteins. Initiation of the viral productive replication requires expression of the E2 viral protein that cooperates with the E1 viral DNA helicase. A novel and important role for the HPV16-E2 protein in controlling host cell cycle during malignant transformation was recently revealed. Xells expressing HPV16-E2 in vitro were arrested in prophase alongside activation of a sustained DDR signal. In vivo, HPV16-E2 protein is present in cells that express both mitotic and DDR signals specifically in CIN3 lesions, immediate precursors of cancer, suggesting that E2 may be one of the drivers of genomic instability and carcinogenesis in vivo.
Format: Liquid
Concentration: 0.9-1.1 mg/ml
Storage buffer: Whole serum
Storage conditions: -15° C to -25° C
Shipping conditions: Dry ice
References:

Xue et al. 2015. Oncotarget. 6(33):34979-91. PMID: 26474276.

HPV16-E2 induces prophase arrest and activates the cellular DNA damage response in vitro and in precursor lesions of cervical carcinoma.

Xue et al. 2010. Cancer Res. 70(13):5316-25. PMID: 20530671.

HPV16 E2 is an immediate early marker of viral infection, preceding E7 expression in precursor structures of cervical carcinoma.

Images

View Gallery
Figure. E2 induces a DNA damage signal in A549 cells arrested in prophase. A. Western blot analyses of lysates from A549 cells expressing GFP-16E2; GFP-18E2; HPV18E2 transactivation domain (GFP-18E2TAD) or the DNA binding domain (GFP-18E2DBD); probed with antibodies against GFP; ?H2AX; Chk2T68 and ATMS1981. B. Confocal microscopy of E2-expressing A549 cells double labeled with anti-?H2AX (light blue) and anti-Chk2T68 (red). White arrows

Related Tools for Antibodies

Cat. # Tool Name
151016 Anti-CyclinA [E72.1] Key Info View Tool
151019 Anti-Mos [S3.1] Key Info View Tool
151024 Anti-Hairy [1/24] Key Info View Tool
151031 Anti-RuvA [RuvA 12C6] Key Info View Tool
151028 Anti-Cytochrome P450 2C2, 2B1/2 [h7] Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.